SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : The Art of Investing -- Ignore unavailable to you. Want to Upgrade?

To: Lou Weed who wrote (3476)1/29/2022 10:18:00 AM
From: Sun Tzu  Respond to of 10711
 
Yes, I consider ARKG, once it stabilizes, as a good candidate for investing in bios. I'd go with LABU or the like for trading.



To: Lou Weed who wrote (3476)3/14/2022 3:06:22 PM
From: Sun Tzu1 Recommendation

Recommended By
Lou Weed

  Respond to of 10711
 
With regards to ARKG, it has been very closely following ARKK. This means that it is not trading as a biotech fund; it is trading based on risk trades and factors based flow of funds.

It is likely that XBI and GERM will bottom before ARKG and (at least initially) provide better returns until ARKG builds a base.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News